A new approach to predicting cognitive impairment

Welcome to the future of Alzheimer's disease testing

The future of Alzheimer's disease (AD) testing is with the innovative VeraBIND™ Tau Pathology* assay. Preliminary results show a high degree of accuracy at detecting tau pathology in cognitively normal, MCI, and those living with AD, by successfully discriminating healthy controls from patients with tau pathology also positive by tau PET imaging. We look forward to further validating these results and delivering this novel blood-based test to help predict cognitive impairment while improving accessibility and reducing cost.

Potential Benefits of the VeraBIND Tau Pathology assay include:

Alternative to tau PET imaging

Helps predict cognitive impairment

Measures tau pathology in EDTA plasma

Improves accessibility and reduces cost

Learn how we’re developing assays that deliver clear and actionable results to help clinicians make informed decisions for those living with AD.

Sign up to receive updates from Veravas

We value your privacy

This test is currently under development and has not yet been validated for clinical use. It is not approved or cleared by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. The performance characteristics of this test have not been established, and it should not be used for patient diagnosis, treatment, or any other clinical purpose. Further development and validation studies are required to ensure the test's accuracy, reliability, and clinical utility.